Jump to the top of the page

Investment Banking

The Quarterly Rx: Q1 2023 U.S. Biopharma Recap

The year kicked off with renewed optimism for the biopharma sector, but “macro” concerns resurfaced to end the quarter. Demand for catalyst-driven offerings remained strong in the public markets, but the private market continued to slow. There is a strong desire to see more SMID-cap M&A to recycle capital into the sector, while reverse mergers continue to provide companies with an alternative path to the public markets. The quarter did see the long-awaited “big M&A” of Seagen by Pfizer, the largest biopharma deal since 2019.

William Blair’s Biopharma team shares perspectives in the Quarterly Rx: Q1 2023 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Arcus Infrastructure Partners Closes Oversubscribed European Infrastructure Fund IV

    William Blair acted as exclusive placement agent to Arcus Infrastructure Partners LLP in connection with its oversubscribed €3.0 billion Fourth Fund, Arcus European Infrastructure Fund 4 SCSp.

    Read more

  • Navigating the Expanding Spectrum of Financing

    William Blair’s Private Capital Markets and Leveraged Finance teams explain the highly flexible bespoke capital solutions available to business owners and sponsors and how to navigate the expanding spectrum of financing.

    Watch the video

  • Powering the Digital Frontier: The Impact of Data Centers on U.S. Energy Demand

    The rapid expansion of data centers is reshaping electricity demand in the U.S. and increasing dependence on natural gas as a primary energy source.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures